作者:Scott D. Kuduk、Christina Ng、Dong-Mei Feng、Jenny M.-C. Wai、Raymond S. L. Chang、Charles M. Harrell、Kathy L. Murphy、Richard W. Ransom、Duane Reiss、Magnus Ivarsson、Glenn Mason、Susan Boyce、Cuyue Tang、Thomayant Prueksaritanont、Roger M. Freidinger、Douglas J. Pettibone、Mark G. Bock
DOI:10.1021/jm049394l
日期:2004.12.1
Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacokinetic properties. Lead compounds were shown to exhibit good efficacy in rabbit in vivo models of pain and inflammation.
缓激肽B1受体拮抗剂体现了一种潜在的新颖方法,可用于治疗慢性疼痛和炎症。优化了一系列的2,3-二氨基吡啶B1拮抗剂,使其具有亚纳摩尔亲和力和良好的药代动力学特性。铅化合物在兔子的疼痛和炎症体内模型中显示出良好的功效。